Hans J. Hammers, MD, PhD, discusses findings from a phase I study of alpha-1, 3 galactosyltransferase-expressing allogeneic RCC immunotherapy.
2017 April
Researchers offer a review of the role of adjuvant or neoadjuvant chemotherapy, targeted therapy, and immunotherapy in localized soft tissue sarcoma.
The use of low-dose radiotherapy may offer transient benefits; nonetheless the potential for palliative care exists.
A locoregional approach to cancer vaccines, when combined with immunmodulatory antibody therapy, could generate a significant anti-tumor response.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
